Merck Serono S.P.A., Italy
8
1
1
4
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 60/100
37.5%
3 terminated/withdrawn out of 8 trials
57.1%
-29.4% vs industry average
50%
4 trials in Phase 3/4
150%
6 of 4 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (8)
Cetuximab Plus Platinum and Taxane-based Chemotherapy, Followed by Avelumab and Cetuximab, as First-line Treatment for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Patients With a PD-L1 Combined Positive Score (CPS)≥1≤19.
Role: collaborator
PERgoveriS In Stratified Treatment for Assisted Reproductive Technique
Role: collaborator
Clinical Performance and Safety Investigation of ENDOmetrial Washing MEdical DEvice Forielle
Role: collaborator
Dietary Supplement of Curcumin in Subjects With Active Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta 1a
Role: collaborator
To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Italy
Role: collaborator
A Pilot Trial of Interferon Beta-1a in Alzheimer's Disease
Role: collaborator
Study to Evaluate if the Addition of r-hLH (Luveris®) to FSH From Day 8 of Ovarian Stimulation is Able to Decrease Total FSH Dose and to Improve Cycle Outcome in Infertile Women Undergoing ART, Who Required High FSH Dose in a Previous Cycle
Role: collaborator
A Trial to Evaluate the Correlation Between Spontaneous Catch-up Growth, Clinical Response to Saizen (Recombinant Human Growth Hormone, r-hGH) and Gene Expression Profiling in Children Small for Gestational Age (SGA)
Role: collaborator
All 8 trials loaded